Eckhard Thiel

Q: What Schools Are Affiliated With Eckhard Thiel

Eckhard Thiel is affiliated with the following schools: TU Dresden, University of Leicester, University of Freiburg, Kiel University, Free University of Berlin, Ruhr University Bochum

Eckhard Thiel's AcademicInfluence.com Rankings

Eckhard Thiel

Philosophy

#5437

World Rank

#8236

Historical Rank

Logic

#2721

World Rank

#3752

Historical Rank

philosophy Degrees

Eckhard Thiel

Biology

#7263

World Rank

#10158

Historical Rank

Microbiology

#353

World Rank

#403

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Eckhard Thiel's Degrees

PhD Microbiology University of Cologne
Doctorate Medicine University of Cologne

Why Is Eckhard Thiel Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Eckhard Thiel's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. (2002) (3019)
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. (2009) (1615)
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. (2002) (840)
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. (2005) (650)
Establishment of a human cell line (mono mac 6) with characteristics of mature monocytes (1988) (610)
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. (2011) (609)
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. (2006) (486)
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. (2010) (476)
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. (2012) (388)
Improved outcome in central nervous system aspergillosis, using voriconazole treatment. (2005) (351)
Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients (2005) (343)
Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. (2002) (336)
Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. (1984) (299)
Improved outcome in adult B-cell acute lymphoblastic leukemia. (1996) (293)
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. (2009) (289)
Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. (1999) (265)
CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. (2002) (260)
Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction (1991) (259)
Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. (2006) (251)
Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma. (2003) (238)
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. (2014) (231)
Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. (1988) (225)
Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. (2007) (224)
Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. (2003) (215)
Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). (2000) (213)
Improved Outcome of Zygomycosis in Patients with Hematological Diseases? (2004) (211)
Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival (2007) (204)
MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease (2010) (202)
Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. (2005) (196)
Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group (1984) (192)
Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity (2004) (186)
Surgery for primary CNS lymphoma? Challenging a paradigm. (2012) (185)
Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. (1998) (178)
BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. (2006) (177)
Long-Term Control of HIV by CCR 5 Delta 32 / Delta 32 Stem-Cell Transplantation (2009) (175)
Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia (1997) (164)
Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial (2002) (163)
Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. (2011) (158)
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. (2002) (157)
Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. (1991) (153)
Effects of endurance training on the physical performance of patients with hematological malignancies during chemotherapy (2003) (153)
Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors (2006) (153)
Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. (2000) (152)
Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. (2007) (150)
CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets (2005) (149)
Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer (2006) (147)
Central nervous system disease in hematologic malignancies: historical perspective and practical applications. (2009) (145)
Norovirus gastroenteritis causes severe and lethal complications after chemotherapy and hematopoietic stem cell transplantation. (2011) (139)
Primary CNS lymphoma with intraocular involvement (2008) (137)
Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. (2005) (135)
Phase 2 Trial of Vaccination With Tyrosinase Peptides and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma (2000) (134)
Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. (1997) (133)
Quantitative real‐time RT‐PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers (2004) (133)
Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. (2008) (131)
Prospective trial on topotecan salvage therapy in primary CNS lymphoma. (2006) (130)
Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. (2002) (129)
Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. (2006) (128)
Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. (1989) (126)
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group (2001) (125)
Multimarker classification of acute lymphoblastic leukemia: evidence for further T subgroups and evaluation of their clinical significance. (1980) (123)
A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. (2011) (123)
In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer (2006) (123)
Acute myeloid leukemias expressing lymphoid-associated antigens: diagnostic incidence and prognostic significance. (1993) (120)
High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. (2006) (117)
Clinical and Immunologic Responses to Active Specific Cancer Vaccines in Human Colorectal Cancer (2006) (117)
Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study. (2002) (117)
Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. (2006) (114)
Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26). (1994) (113)
Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment. (2004) (112)
Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. (2006) (110)
Effects of an endurance and resistance exercise program on persistent cancer-related fatigue after treatment. (2008) (108)
Deep venous thrombosis and pulmonary artery embolism in high‐grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance (1995) (104)
CXCL13 and CXCL12 in Central Nervous System Lymphoma Patients (2009) (102)
Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. (1992) (102)
Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas (2013) (102)
High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. (2005) (101)
Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors. (1998) (100)
Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. (2007) (100)
Quantitative Detection of Circulating Tumor Cells in Cutaneous and Ocular Melanoma and Quality Assessment by Real-Time Reverse Transcriptase-Polymerase Chain Reaction (2004) (99)
FLT3 Mutations in Early T-Cell Precursor ALL Characterize a Stem Cell Like Leukemia and Imply the Clinical Use of Tyrosine Kinase Inhibitors (2013) (98)
Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (1996) (96)
Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2. (2011) (96)
Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study (2007) (95)
Meningeal dissemination in primary CNS lymphoma (2008) (90)
The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group. (2009) (90)
The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. (2006) (90)
Long-Term Follow-up of Adults with Acute Lymphoblastic Leukemia in First Remission Treated with Chemotherapy or Bone Marrow Transplantation (1995) (89)
The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia. (2011) (88)
CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes (2002) (88)
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma (2015) (87)
Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents (2011) (86)
Functional CCR9 expression is associated with small intestinal metastasis. (2004) (86)
Efficacy of the interleukin‐2 receptor antagonist basiliximab in steroid‐refractory acute graft‐versus‐host disease (2005) (86)
Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma. (2016) (86)
Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib (2009) (84)
Favorable response of early stage B CLL patients to treatment with IFN-alpha 2. (1989) (84)
Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10−/CD24−/CD65s+/CD15+ B-cell phenotype (2003) (83)
Intraocular lymphoma 2000–2005: results of a retrospective multicentre trial (2006) (82)
Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases (2008) (82)
Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation (2007) (81)
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. (2004) (80)
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer (2005) (80)
Circulating Tumor Cells as Prognostic Factor for Distant Metastases and Survival in Patients with Primary Uveal Melanoma (2007) (79)
Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20+ B-Lineage Standard and High Risk Patients; Results of 263 CD20+ Patients Studied Prospectively In GMALL Study 07/2003 (2010) (79)
Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. (2006) (78)
Effects of granulocyte‐macrophage colony‐stimulating factor and foreign helper protein as immunologic adjuvants on the T‐cell response to vaccination with tyrosinase peptides (2003) (78)
Expression of the WT1 Wilms' tumor gene by normal and malignant human melanocytes (1994) (78)
Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. (2011) (77)
A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. (2006) (77)
Flow cytometric determination of intracellular or secreted IFNγ for the quantification of antigen reactive T cells (2001) (76)
Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias. (1997) (74)
CNS Hodgkin lymphoma. (2008) (74)
Nerve growth factor stimulates clonal growth of human lung cancer cell lines and a human glioblastoma cell line expressing high-affinity nerve growth factor binding sites involving tyrosine kinase signaling. (1995) (74)
Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. (2008) (73)
A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. (2006) (73)
Dual effects of arsenic trioxide (As2O3) on non‐acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation (2002) (72)
Quantification of Tumor-Specific T Lymphocytes With the ELISPOT Assay (2000) (71)
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits (2008) (71)
Analyses of phenotype and genotype in acute lymphoblastic leukemias at first presentation and in relapse. (1987) (71)
Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia (2009) (71)
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. (2007) (69)
Application of the IFN-γ ELISPOT assay to quantify T cell responses against proteins (2001) (69)
Cerebral aspergillosis: tissue penetration is the key. (2009) (69)
Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion (2010) (69)
Immunological Diagnosis of Leukemias and Lymphomas (1977) (67)
Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance. (1999) (67)
International study on low‐grade primary central nervous system lymphoma (2006) (66)
Bone marrow contains melanoma-reactive CD8+ effector T cells and, compared with peripheral blood, enriched numbers of melanoma-reactive CD8+ memory T cells. (2003) (66)
Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia. (2011) (66)
Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management. (2008) (64)
Recombinant human stem cell factor stimulates growth of a human glioblastoma cell line expressing c-kit protooncogene. (1992) (63)
Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations (2006) (63)
Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia (1997) (62)
Poor efficacy of amphotericin B‐based therapy in CNS aspergillosis (2007) (62)
Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia (2010) (62)
Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization (2013) (61)
Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial (2012) (61)
Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. (2011) (60)
Identification of a Highly Immunogenic HLA-A*01-Binding T Cell Epitope of WT1 (2006) (60)
High frequencies of circulating melanoma‐reactive CD8+ T cells in patients with advanced melanoma (2000) (59)
Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features (2005) (59)
2 Immunophenotypic classification of acute lymphoblastic leukaemia (1994) (58)
Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. (2001) (58)
Recombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo. (1993) (58)
Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. (1995) (57)
High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. (2010) (56)
Mycophenolate mofetil for severe autoimmune haemolytic anemia (1997) (55)
Clinical presentation of invasive aspergillosis (1997) (54)
Classification of leukemic cells with T- and O-ALL-specific antisera. (1977) (54)
Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort. (2010) (54)
Low‐grade primary central nervous system lymphoma in immunocompetent patients (2005) (53)
Ph1 -positive CML associated with megakaryocytic hyperplasia and thrombocythemia and an abnormality of chromosome no. 3. (1982) (53)
Independent prognostic factors for distant metastases and survival in patients with primary uveal melanoma. (2004) (53)
Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma (2005) (53)
Progressive Multifocal Leukoencephalopathy with Detection of JC Virus in a Patient with Chronic Lymphocytic Leukemia Parallel to Onset of Fludarabine Therapy (2003) (53)
Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group. (1993) (52)
Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. (2007) (52)
The German multicentre trials for treatment of acute lymphoblastic leukemia in adults. The German Adult ALL Study Group. (1992) (52)
Decrease and altered distribution of human T antigen on chronic lymphatic leukemia cells of T type, suggesting a clonal origin. (1976) (52)
Autocrine interleukin‐1 receptor antagonist can support malignant growth of glioblastoma by blocking growth‐inhibiting autocrine loop of interleukin‐1 (1997) (51)
CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL). (2005) (51)
Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group. (1991) (50)
Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13. (1996) (50)
The K+ channel openers diazoxide and NS1619 induce depolarization of mitochondria and have differential effects on cell Ca2+ in CD34+ cell line KG-1a. (2003) (50)
Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial (2017) (50)
First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. (2009) (49)
Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma. (2005) (49)
Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer (2008) (48)
Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia. (1997) (48)
Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome (2010) (48)
Immunophenotypic features of childhood and adult acute lymphoblastic leukemia (ALL): experience of the German Multicentre Trials ALL-BFM and GMALL. (1994) (47)
A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors (2005) (46)
Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. (2012) (46)
CMV‐specific central memory T cells reside in bone marrow (2007) (45)
Prediction of qualitative outcome of oligonucleotide microarray hybridization by measurement of RNA integrity using the 2100 Bioanalyzer™ capillary electrophoresis system (2009) (45)
C-kit, GIST, and imatinib. (2007) (45)
Thymic adult T-cell acute lymphoblastic leukemia stratified in standard- and high-risk group by aberrant HOX11L2 expression: experience of the German multicenter ALL study group (2008) (45)
Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma (2005) (45)
Detection of HRX-FEL fusion transcripts in pre-pre-B-ALL with and without cytogenetic demonstration of t(4;11). (1994) (45)
Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan (2004) (45)
Insertional polymorphisms of endogenous HERV-K113 and HERV-K115 retroviruses in breast cancer patients and age-matched controls. (2004) (45)
Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2. (2006) (45)
Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia (2010) (44)
Immunocytochemical identification of meningeal leukemia and lymphoma: poly-L-lysine-coated slides permit multimarker analysis even with minute cerebrospinal fluid cell specimens. (1989) (44)
Expression of Wilms’ tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants (2004) (44)
Atypical BCR-ABL mRNA transcripts in adult Acute lymphoblastic leukemia (2007) (43)
Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system (2005) (43)
Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma (2004) (42)
Cryptococcosis in Hodgkin's disease: description of two cases and review of the literature (1998) (42)
Extrapulmonary small cell carcinoma (EPSCC): 10 years' multi-disciplinary experience at Charité. (2009) (42)
Immunophenotypic and Genotypic Features , Clinical Characteristics , and Treatment Outcome of Adult ProB Acute Lymphoblastic Leukemia : Results of the German Multicenter Trials (1998) (41)
The role of LHRH-analogues in protecting gonadal functions during chemotherapy and irradiation. (1993) (41)
Update on the treatment of cerebral aspergillosis. (2004) (41)
Treatment of relapsed or refractory adult acute lymphocytic leukemia (1992) (41)
Hydrops lysosomalis generalisatus – an underestimated side effect of hydroxyethyl starch therapy? (2006) (41)
Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. (2015) (40)
Differences in T‐cell immunity toward tumor‐associated antigens in colorectal cancer and breast cancer patients (2003) (40)
Activated K‐ras is involved in regulation of integrin expression in human colon carcinoma cells (2000) (40)
Acute Myeloid Leukemia with Translocation (8;21). Cytomorphology, Dysplasia and Prognostic Factors in 41 Cases (1996) (40)
Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104). (2005) (39)
Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG. (1996) (39)
Radiologic morphology of low-grade primary central nervous system lymphoma in immunocompetent patients. (2005) (39)
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma (2007) (39)
High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. (2011) (39)
Quality assurance in RT-PCR-based BCR/ABL diagnostics – results of an interlaboratory test and a standardization approach (2000) (39)
Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro (1991) (39)
Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2. (1999) (38)
Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. (2010) (38)
Central nervous system infections in immunocompromised patients – update on diagnostics and therapy (2009) (38)
Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors (2004) (38)
Diagnosis and management of primary intraocular lymphoma: an update (2007) (37)
High rate of chromosome abnormalities detected by fluorescence in situ hybridization using BCR and ABL probes in adult acute lymphoblastic leukemia (1998) (37)
Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis (2009) (37)
Application of the IFN-gamma ELISPOT assay to quantify T cell responses against proteins. (2001) (37)
Prognostic Relevance of Circulating Tumor Cells in Metastatic Uveal Melanoma (2011) (37)
Brain and whole-body FDG-PET in diagnosis, treatment monitoring and long-term follow-up of primary CNS lymphoma (2013) (37)
HD37 Monoclonal Antibody: A Useful Reagent for Further Characterization of “Non-T, Non-B” Lymphoid Malignancies (1986) (37)
Transplantation of selected or transgenic blood stem cells – a future treatment for HIV/AIDS? (2009) (36)
Skewed expression of natural‐killer (NK)‐associated antigens on lymphoproliferations of large granular lymphocytes (LGL) (2006) (36)
DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation. (2007) (36)
Rabbit antithymocyte globulin (Thymoglobulin®) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients (2013) (36)
The type of ATG matters -- natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius. (2007) (36)
Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia (2016) (36)
Rational peptide-based tumour vaccine development and T cell monitoring. (2003) (35)
Subtypes of T‐cell chronic lymphatic leukemia (1983) (35)
Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma. (1990) (35)
Possible regulation of Wilms’ tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA‐1 in human acute myeloid leukaemias (2003) (35)
Synergistic antitumor interactions between newly synthesized ruthenium complexes and cytokines in human colon carcinoma cell lines. (1992) (35)
A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma (2005) (35)
Identification of known and novel immunogenic T‐cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL‐2‐based treatment (2002) (35)
Primary central nervous system (CNS) lymphoma in immunocompetent patients (2002) (35)
Immunological monitoring of cancer vaccine therapy (2004) (35)
Empirical antimicrobial monotherapy in patients after high‐dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial (2005) (34)
Frequency and Clinical Significance of DNA Aneuploidy in Acute Leukemia (1986) (34)
Ifosfamide or trofosfamide in patients with intraocular lymphoma (2008) (34)
Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. (1996) (34)
Efficacy and Tolerability of Alemtuzumab (CAMPATH-1H) in the Salvage Treatment of B-Cell Chronic Lymphocytic Leukemia—Change of Regimen Needed? (2004) (33)
Quantitative immunoautoradiography at the cellular level. I. Design of a microphotometric method to quantitate membrane antigens on single cells using 125I-labeled antibodies. (1975) (33)
Ertumaxomab: a trifunctional antibody for breast cancer treatment. (2008) (33)
T cell responses against tumor associated antigens and prognosis in colorectal cancer patients (2005) (33)
Intensified Strategies to Control Vancomycin-Resistant Enterococci in Immunocompromised Patients (2007) (33)
Wilms Tumor Gene (WT1) Expression as a Panleukemic Marker (2002) (33)
Atypical generalized eruptive histiocytosis associated with acute monocytic leukemia. (2003) (32)
Chemopurging of peripheral blood-derived progenitor cells by alkyl-lysophospholipid and its effect on haematopoietic rescue after high-dose therapy. (1996) (32)
Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial (2009) (32)
Evaluation of late cardiotoxicity with pulsed Doppler echocardiography in patients treated for Hodgkin's disease (1993) (32)
Successful Subtype Oriented Treatment Strategies in Adult T-All; Results of 744 Patients Treated in Three Consecutive GMALL Studies. (2009) (31)
Mitoxantrone and high‐dose cytarabine as salvage therapy for refractory non‐Hodgkin's lymphoma (1989) (31)
Fractionated Irradiation Can Induce Functionally Relevant Multidrug Resistance Gene and Protein Expression in Human Tumor Cell Lines (2005) (31)
Ifosfamide/liposomal daunorubicin is a well tolerated and active first‐line chemotherapy regimen in advanced soft tissue sarcoma (2005) (31)
Expression of interleukin 15 in primary adult acute lymphoblastic leukemia (2010) (31)
The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems (1997) (31)
Recombinant human stem cell factor does exert minor stimulation of growth in small cell lung cancer and melanoma cell lines. (1995) (31)
Tritium radiolabeling of antibodies to high specific activity with N-succinimidyl [2,3-3H] propionate: use in detecting monoclonal antibodies. (1981) (31)
Fatal spleen rupture during induction chemotherapy with rh GM-CSF priming for acute monocytic leukemia. Clinical case report and in vitro studies. (1993) (31)
Adhesion molecules on peripheral blood-derived CD34+ cells: effects of cryopreservation and short-term ex vivo incubation with serum and cytokines (1998) (31)
Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS. (2010) (30)
A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma (2004) (30)
Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. (2015) (30)
Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer. (2007) (29)
Reliability of PCR-based detection of occult tumour cells: lessons from real-time RT-PCR (2001) (29)
CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy (2009) (28)
Stem cell mobilization in multiple myeloma patients: Do we need an age‐adjusted regimen for the elderly? (2004) (28)
Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms. (2009) (28)
Wilms’ tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome (2009) (27)
High levels of 5'-nucleotidase activity in blastic chronic myelogenous leukemia with common ALL-antigen. (1981) (27)
Auer rod‐like intracytoplasmic inclusions in multiple myeloma. A case report and review of the literature (2009) (27)
Morphological and cytochemical findings in 150 cases of T‐lineage acute lymphoblastic leukaemia in adults (1997) (27)
Identification and quantitation of human T-cell antigen by antisera purified from antibodies crossreacting with hemopoietic progenitors and other blood cells (1975) (27)
CD82 (KAI1), a member of the tetraspan family, is expressed on early haemopoietic progenitor cells and up‐regulated in distinct human leukaemias (1999) (27)
Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data (2001) (27)
Integrin α5β1: a potent inhibitor of experimental lung metastasis (1998) (27)
The diagnostic value of cerebrospinal fluid pleocytosis and protein in the detection of lymphomatous meningitis in primary central nervous system lymphomas. (2006) (27)
Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan (2006) (27)
Primary central nervous system lymphomas (PCNSL): MRI response criteria revised (2005) (27)
Immunophenotypic classification of acute lymphoblastic leukaemia. (1994) (27)
Culturing human umbilical cord blood: a comparison of mononuclear vs CD34+ selected cells (1999) (26)
Methods of quantitative autoradiography using incident light microphotometry. (1976) (26)
TRANSPLANTATION OF SYNGENEIC BONE MARROW INCUBATED WITH LEUKOCYTE ANTIBODIES: II. CYTOTOXIC ACTIVITY OF ANTI‐cALL GLOBULIN ON LEUKEMIC CELLS AND NORMAL HEMOPOIETIC PRECURSOR CELLS IN MAN (1978) (26)
Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee. (1995) (26)
CD 8 T-cell responses to Wilms tumor gene product WT 1 and proteinase 3 in patients with acute myeloid leukemia (2002) (26)
Distinction of eosinophilic leukaemia from idiopathic hypereosinophilic syndrome by analysis of Wilms' tumour gene expression (1998) (26)
Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populations (2008) (26)
Epigenetic dysregulation of GATA1 is involved in myelodysplastic syndromes dyserythropoiesis (2012) (26)
Biochemical modulation of cytotoxic drugs by cytokines: molecular mechanisms in experimental oncology. (1995) (26)
Aleukemic Mast Cell Leukemia with Abnormal Immunophenotype and C-kit Mutation D816V (2004) (26)
Teniposide (VM-26) and cytosine arabinoside as consolidation therapy in adult high-risk patients with acute lymphoblastic leukemia. (1987) (25)
Subtype Adjusted Therapy Improves Outcome of Elderly Patients with Acute Lymphoblastic Leukemia (ALL). (2004) (25)
Efficacy and Pharmacologic Data of Second-Generation Tyrosine Kinase Inhibitor Nilotinib in BCR-ABL-Positive Leukemia Patients with Central Nervous System Relapse after Allogeneic Stem Cell Transplantation (2014) (25)
Trisomy 12 in B-cell chronic lymphocytic leukemia: correlation with advanced disease, atypical morphology, high levels of sCD25, and with refractoriness to treatment. (1995) (25)
Bloodstream infections in neutropenic patients: early detection of pathogens and directed antimicrobial therapy due to surveillance blood cultures. (2007) (25)
“Wilms Tumor Protein 1” (WT1) Peptide Vaccination-induced Complete Remission in a Patient With Acute Myeloid Leukemia Is Accompanied by the Emergence of a Predominant T-cell Clone Both in Blood and Bone Marrow (2011) (25)
Aclarubicin (aclacinomycin A) in the treatment of relapsing acute leukaemias. (1985) (25)
Gonadal toxicity following cancer therapy in adults: significance, diagnosis, prevention and treatment. (1990) (24)
Chromosomal abnormalities in adult acute lymphoblastic leukemia: results of the German ALL/AUL Study Group. (1993) (24)
Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment. (2004) (24)
Rearrangements of T-cell receptor delta, gamma and beta genes in acute myeloid leukemia coexpressing T-lymphoid features. (1992) (23)
Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up. (2008) (23)
Growth of the Reh cell line in diffusion chambers. Evidence for differentiation along the T- and B-cell pathway. (2009) (23)
Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor. (1992) (23)
Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. (1999) (23)
Long‐term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides (2002) (23)
Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen. (1997) (22)
False-positive Aspergillus antigen testing due to application of piperacillin/tazobactam--is it still an issue? (2008) (22)
Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia (2005) (22)
Lack of evidence that false-positive Aspergillus galactomannan antigen test results are due to treatment with piperacillin-tazobactam. (2004) (22)
A phase II trial of interferon α-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma (1992) (22)
Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia (2017) (22)
Genetic variants of folate and methionine metabolism and PCNSL incidence in a German patient population (2010) (22)
Immunomagnetic selection of CD34+ cells from fresh peripheral blood mononuclear cell preparations using two different separation techniques. (1995) (22)
Detection of Immunoglobulin Heavy Chain Genes Rearrangements in B-Cell Leukemias, Lymphomas, Multiple Myelomas, Monoclonal and Polyclonal Gammopathies (2000) (22)
Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells. (2001) (22)
Testicular germ cell tumor with rhabdomyosarcoma successfully treated by disease-adapted chemotherapy including high-dose chemotherapy: case report and review of the literature (2001) (21)
De novo expression of the α5β1‐fibronectin receptor in HT29 colon‐cancer cells reduces activity of c‐src. Increase of c‐src activity by attachment on febronectin (1998) (21)
The effect of crude and differently absorbed anti-human T-cell globulin on granulocytic and erythropoietic colony formation. (1978) (21)
Cytogenetic studies in acute leukemia patients relapsing after allogeneic stem cell transplantation. (2010) (21)
Specific absorbed antithymocyte globulin for incubation treatment in human marrow transplantation. (1977) (21)
The Use of Hirudin as Universal Anticoagulant in Haematology, Clinical Chemistry and Blood Grouping (2001) (21)
Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation (2008) (21)
Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma. (2005) (21)
Expression of IGFBP7 in acute leukemia is regulated by DNA methylation (2011) (21)
Interferon‐alpha 2b (IFNα) for Early‐Phase Chronic Lymphocytic Leukaemia with High Risk for Disease Progression: Results of a Randomized Multicentre Study (1996) (21)
Erroneous class switching and false VDJ recombination: Molecular dissection of t(8;14)/MYC‐IGH translocations in Burkitt‐type lymphoblastic leukemia/B‐cell lymphoma (2013) (21)
Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma (2009) (20)
Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial (2015) (20)
Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination (2010) (20)
Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group. (1990) (20)
Primary central nervous system lymphoma (2008) (20)
Intracellular Cytokine Staining (2005) (20)
Ultrastructural demonstration of peroxidase expression in acute unclassified leukemias: correlation to immunophenotype and treatment outcome. (1991) (20)
Visceral Leishmaniasis mimicking a flare of systemic lupus erythematosus (1991) (20)
Common clonal T‐cell origin in a patient with T‐prolymphocytic leukaemia and associated cutaneous T‐cell lymphomas (2003) (20)
Prognostic implication of Ecto‐5′‐nucleotidase activity in acute lymphoblastic leukemia (1990) (20)
Quantitative immunoautoradiography at the cellular level. II. Absolute measurements using labeled standard cells as a source of reference. (1976) (20)
Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy. (1998) (20)
HLA typing demands for peptide-based anti-cancer vaccine (2008) (20)
Molecular diagnosis of the Philadelphia chromosome in chronic myelogenous and acute lymphoblastic leukemias by PCR. (1990) (20)
Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. (1994) (20)
Quantitative nested real-time RT-PCR specific for tyrosinase transcripts to quantitate minimal residual disease. (2002) (19)
Ertumaxomab: a trifunctional antibody for breast cancer treatment (2008) (19)
Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines (2012) (19)
Epigenetic control of differential expression of specific ERG isoforms in acute T-lymphoblastic leukemia. (2009) (19)
CNS-aspergillosis: are there new treatment options? (2003) (19)
Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro (2009) (19)
Interactions between cytokines and cytotoxic drugs: putative molecular mechanisms in experimental hematology and oncology. (1992) (19)
Treatment of primary intraocular lymphoma with oral trofosfamide: report of two cases and review of the literature (2004) (19)
Mutation Analysis of hCDC4 in AML Cells Identifies a New Intronic Polymorphism (2006) (19)
Integrin alpha5beta1: a potent inhibitor of experimental lung metastasis. (1998) (19)
Epigenetic regulation of PAX5 expression in acute T-cell lymphoblastic leukemia. (2011) (19)
A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours. (2004) (18)
Genome-wide DNA-mapping of CD34+ cells from patients with myelodysplastic syndrome using 500K SNP arrays identifies significant regions of deletion and uniparental disomy. (2009) (18)
Neomycin as secondary prophylaxis for irinotecan-induced diarrhea. (2004) (18)
Intrathecal application of donor lymphocytes in leukemic meningeosis after allogeneic stem cell transplantation (2011) (18)
transplantation Evidence for the cure of HIV infection by CCR5{Delta}32/{Delta}32 stem cell (2010) (18)
Cytochemistry and membrane markers in acute lymphatic leukaemia (ALL). (2009) (18)
Nested quantitative real time PCR for detection of occult tumor cells. (2001) (18)
Human gene therapy in gastrointestinal diseases: in vivo and in vitro approaches. (1996) (17)
Quantitation of T-antigenic sites and Ig-determinants on leukemic cells by microphotometric immunoautoradiography. Proof of the clonal origin of thymus-derived lymphocytic leukemias. (1977) (17)
Flow cytometric CD34+ determination in stem cell transplantation: before or after cryopreservation of grafts? (2002) (17)
Induction of tyrosinase‐reactive T cells by treatment with dacarbazine, cisplatin, interferon‐alpha ± interleukin‐2 in patients with metastatic melanoma (1999) (17)
Myeloid antigens and antigen densities in mice and men. (1977) (17)
Flow cytometric analysis of the binding of eleven lectins to human T- and B-cells and to human T- and B-cell lines. (1984) (17)
Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system (2009) (17)
Non-enhancing relapse of a primary CNS lymphoma with multiple diffusion-restricted lesions (2011) (17)
Depolarization of mitochondria and activation of caspases are common features of arsenic(III)-induced apoptosis in myelogenic and lymphatic cell lines. (2004) (16)
Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation (2007) (16)
Production of bifunctional single-chain antibody-based fusion proteins in Pichia pastoris supernatants (2008) (16)
A 19‐year‐old Male with Generalized Seizures, Unconsciousness and a Deviation of Gaze (2006) (16)
An intron 9 containing splice variant of PAX2 (2009) (16)
Spontaneous Epstein-Barr virus transformed B-cell line sharing the identical immunoglobulin gene rearrangement with acute myeloid leukemia. (1989) (16)
Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome. (2006) (16)
Treatment options for central nervous system lymphomas in immunocompetent patients (2009) (16)
The role of mitochondrial targeting in arsenic trioxide‐induced apoptosis in myeloid cell lines (2004) (16)
Restricted T-cell receptor repertoire in melanoma metastases regressing after cytokine therapy. (2003) (16)
Quantitative real-time RT-PCR detects elevated Wilms tumor gene (WT1) expression in autologous blood stem cell preparations (PBSCs) from acute myeloid leukemia (AML) patients indicating contamination with leukemic blasts (2002) (15)
Endogenous filamentous fungal endophthalmitis – single‐centre survey in patients with acute leukaemia or postallogeneic stem cell transplantation and review of the literature (2011) (15)
A33scFv-green fluorescent protein, a recombinant single-chain fusion protein for tumor targeting. (2007) (15)
Cell surface markers in leukemia: biological and clinical correlations. (1985) (15)
Serum levels of interleukin-10 in B-cell chronic lymphocytic leukemia [letter; comment] (1995) (15)
Clinical relevance of blast cell phenotype as determined with monoclonal antibodies in acute lymphoblastic leukemia of adults. (1987) (15)
Recent Advances in Cell Biology of Acute Leukemia (1993) (15)
Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine. (2004) (15)
Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples. (1992) (15)
New Definition of Treatment Response in Adult Acute Lymphoblastic Leukemia (ALL): Use of Molecular Markers for Minimal Residual Disease (MRD). (2009) (15)
Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high-dose methotrexate (2009) (14)
[Quantitative 125-I-autoradiography of individual cells (author's transl)]. (1975) (14)
Human Bone Marrow as a Source to Generate CMV-specific CD4+ T Cells With Multifunctional Capacity (2009) (14)
Peptide vaccination after repeated resection of metastases can induce a prolonged relapse‐free interval in melanoma patients (2005) (14)
CD34 EXPRESSION IN DE NOVO ACUTE MYELOID LEUKAEMIA (1993) (14)
Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemia. (1997) (14)
Prophylactic i.v. Igs in patients with a high risk for CMV after allo-SCT (2009) (14)
Sequential Trimetrexate, 5-Fluorouracil and Folinic Acid Are Effective and Well Tolerated in Metastatic Colorectal Carcinoma (2000) (14)
Serum levels of interleukin-10 in B-cell chronic lymphocytic leukemia. (1995) (13)
Analysis with monoclonal antibodies of human lymphoid cells forming rosettes with rabbit red blood cells. (1983) (13)
Spinal paraparesis due to leukemic meningitis in early-stage chronic lymphocytic leukemia (2005) (13)
A PCR primer system for detecting oncoretroviruses based on conserved DNA sequence motifs of animal retroviruses and its application to human leukaemias and lymphomas. (2001) (13)
Immunophenotype of acute myeloid leukemia: correlation with morphological characteristics and therapy response. (1993) (13)
Systemic Immune Tuning in Renal Cell Carcinoma: Favorable Prognostic Impact of TGF-&bgr;1 mRNA Expression in Peripheral Blood Mononuclear Cells (2011) (13)
Antiproliferative effect of human interleukin-4 in human cancer cell lines: studies on the mechanism. (1995) (13)
Intramedullary abscess in a patient with disseminated Scedosporium apiospermum infection (2003) (12)
No genetic evidence for involvement of Deltaretroviruses in adult patients with precursor and mature T-cell neoplasms (2007) (12)
Differential effects of a stem cell factor-immunoglobulin fusion protein on malignant and normal hematopoietic cells. (1999) (12)
Arsenic trioxide-induced apoptosis is independent of CD95 in lymphatic cell lines. (2004) (12)
Incidence and clinical implications of acute hybrid leukemia in childhood. (1990) (12)
Morphological and cytochemical classification of adult acute leukemias in two multicenter studies in the Federal Republic of Germany. (1987) (12)
Detection of immunoglobulin heavy chain gene rearrangements in hematologic malignancies (2001) (12)
Rearrangement of T cell receptor beta, gamma, and delta gene loci in human pre-T cell acute lymphoblastic leukemia. (1989) (12)
Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patients (2010) (11)
Combined automated cell and flow cytometric analysis enables recognition of persistent polyclonal B-cell lymphocytosis (PPBL), a study of 25 patients (2008) (11)
Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo (1993) (11)
Biodistribution and efficacy of [131I]A33scFv::CDy, a recombinant antibody-enzyme protein for colon cancer. (2008) (11)
Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells. (1993) (11)
[Acute lymphatic leukemia of the adult. Diagnosis, risk groups and therapy]. (1996) (11)
HLA-A2 expression, stage, and survival in colorectal cancer (2008) (11)
Comparison of ethidium bromide-stained agarose gel electrophoresis and automated fragment analysis for evaluation of IgH gene products. (2001) (11)
Specific Central Memory T Cells in the Bone Marrow of Patients Immunized Against Tyrosinase Peptides (2006) (11)
Phase I Dose Escalation Study of Carboplatin to a Fixed Dose of Irinotecan as First-Line Treatment of Small Cell Lung Cancer (2004) (10)
Effect of interleukin-3 and granulocyte-macrophage colony-stimulating factor on growth of xenotransplanted human tumour cell lines in nude mice. (1992) (10)
High correlation of the proteome patterns in bone marrow and peripheral blood blast cells in patients with acute myeloid leukemia (2009) (10)
Fatal Mucor pneumonia after treatment with 2-chlorodeoxyadenosine for non-Hodgkin's-lymphoma (1996) (10)
Antibody therapy in non-Hodgkin's lymphoma: the role of rituximab, 90Y-ibritumomab tiuxetan, and alemtuzumab. (2007) (10)
Identification of truncated chemokine receptor 7 in human colorectal cancer unable to localize to the cell surface and unreactive to external ligands (2008) (10)
Increased soluble urokinase plasminogen activator receptor (suPAR) serum levels after granulocyte colony-stimulating factor treatment do not predict successful progenitor cell mobilization in vivo. (2006) (10)
Substantially Improved Outcome of Adult Burkitt Non-Hodgkin Lymphoma and Leukemia Patients with Rituximab and a Short-Intensive Chemotherapy; Report of a Large Prospective Multicenter Trial (2012) (10)
Reversible Ageusia after Chemotherapy with Pegylated Liposomal Doxorubicin (2004) (10)
Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells (2007) (10)
Chromosomal aberrations characteristic for sAML/sMDS are not detectable by random screening using FISH in peripheral blood-derived grafts used for autologous transplantation. (2000) (10)
Molecular analysis of the t(2;8)/MYC–IGK translocation in high‐grade lymphoma/leukemia by long‐distance inverse PCR (2012) (10)
Targeted therapy and blood-brain barrier. (2007) (9)
Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. (2012) (9)
German Multicenter Study Group for Adult ALL (GMALL): recruitment in comparison to ALL incidence and its impact on study results (2002) (9)
Ex vivo expansion of human umbilical cord blood does not lead to co-expansion of contaminating maternal mononuclear cells (1997) (9)
Clinical importance of T-ALL subclassification according to thymic or prethymic maturation stage. (1990) (9)
IL-4 and TNF-alpha induce changes in integrin expression and adhesive properties and decrease the lung-colonizing potential of HT-29 colon carcinoma cells. (1996) (9)
Carboxypeptidase G2 rescue in a 79 year-old patient with cranial lymphoma after high-dose methotrexate induced acute renal failure. (1999) (9)
Multiple myeloma in a patient at risk for AIDS. (1990) (9)
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines (2012) (9)
Molecular genetics in acute and chronic leukemias (2001) (9)
Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up study in 94 stage IV melanoma patients. (2003) (9)
Guillain-Barre-Strohl Syndrome Unraveled as Paraneoplastic Syndrome of B-cell Acute Lymphoblastic Leukemia in a Patient with Preceding Common Variable Immunodeficiency Syndrome with Evans Syndrome (2004) (9)
To protect and defend: central nervous system prophylaxis in patients with non-Hodgkin's lymphoma. (2008) (9)
Purification of human monocytes by adherence to polymeric fluorocarbon. Characterization of the monocyte-enriched cell fraction. (1982) (9)
Prognostic significance of glucocorticoid receptor determination in patients with chronic lymphocytic leukemia and immunocytoma--lack of a positive correlation between receptor levels and clinical responsiveness. (1990) (9)
Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML) (1988) (9)
The Role of Microrna-196a-1 and Microrna-196b in Acute T-Lymphoblastic Leukemia and Acute Myeloid Leukemia. (2009) (9)
Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies (2010) (9)
Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors (2011) (9)
Use of specific antisera against leukemia-associated antigens in the diagnosis of childhood acute lymphoblastic leukemia. (1979) (8)
Images in clinical medicine. Palate destruction by Aspergillus. (1997) (8)
Unusual sites of Hodgkin's lymphoma: CASE 3. Cholemic nephrosis in Hodgkin's lymphoma with liver involvement. (2004) (8)
Incidence, Biologic Features and Treatment Outcome of Myeloid-Antigen-Positive Acute Lymphoblastic Leukemia (My + ALL) (1994) (8)
Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized phase III trial (G-PCNSL-SG-1). (2011) (8)
Allogeneic Stem Cell Transplantation Confers a Favorable Outcome in Patients with NPM1 Positive Acute Myeloid Leukemia: Results From a Donor Vs. No-Donor Analysis of 309 Patients Treated in the SAL AML-2003 Trial (2011) (8)
Idiopathic refractory sideroachrestic anemia (IRSA) progressing to acute mixed lymphoblastic-myelomonoblastic leukemia (2004) (8)
Fine structure of translocation breakpoints within the major breakpoint region in BCR-ABL1-positive leukemias. (2011) (8)
Targeting Folates by Carboxypeptidase G2: Potential Applications in Anticancer Therapy (2000) (8)
Auer-bodies in acute lymphocytic leukemia (ALL) (1980) (8)
[Malignant histiocytosis (author's transl)]. (1978) (8)
High Rate of FLT3 Mutations In Adult ETP-ALL. (2010) (8)
Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group. (1993) (8)
Phenotypic changes in acute lymphoblastic leukemia cells of the common type in diffusion chambers. (1980) (8)
Improved Outcome in Adult T-ALL by Risk Adapted Treatment Strategies. (2004) (8)
Immunologic markers for classification of leukemias and non-Hodgkin lymphomas. (1979) (8)
Identification of an Immunogenic HLA-A*0201-binding T-cell Epitope of the Transcription Factor PAX2 (2009) (8)
Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas. (1996) (8)
[Clubbed fingers and arthralgia as a reversible paraneoplastic syndrome (Pierre-Marie-Bamberger syndrome) in non-small-cell bronchial carcinoma]. (2008) (8)
Homogeneously staining chromosomal region in a case of erythroleukaemia. (2009) (7)
Multicentre pilot study for therapy of acute lymphoblastic and acute undifferentiated leukemia in adults. (1983) (7)
CD34 selected alloPBSCT and adoptive immunotherapy (2000) (7)
A MLL-KIAA0284 fusion gene in a patient with secondary acute myeloid leukemia and t(11;14)(q23;q32). (2008) (7)
Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma. (2006) (7)
Mutation and expression of the p53 tumor suppressor gene in tumor samples and cancer cell-lines - comparison of nonisotopic direct DNA-sequencing, immunoblotting and immunohistochemistry. (1993) (7)
Molecular genetic events in adult acute lymphoblastic leukemia (2003) (7)
Value of surveillance blood cultures in neutropenic patients--a pilot study. (2005) (7)
MDR-1 Expression and Deletions of Chromosomes 7 and 5(Q) Separately Indicate Adverse Prognosis in AML (2001) (7)
Classification of normal and malignant lymphatic cells using acid phosphatase and acid esterase (1980) (7)
Myeloid membrane markers. I. Expression of marker antigens specific for murine granulocytes and their precursor cells. (1977) (7)
Clinical and immune responses of WT1-peptide vaccination in patients with acute myeloid leukemia. (2006) (7)
Phase II trial of N-(phosphonacetyl)-l-aspartate (PALA), 5-fluorouracil and recombinant interferon-α-2b in patients with advanced gastric carcinoma (1996) (7)
Urokinase-type plasminogen-activator (upa), a protease with cytokine-like activity in human hl-60 leukemic-cell line. (1993) (7)
Simultaneous demonstration of two antigens on single T cells using antibodies with contrasting labels. (1986) (7)
Upfront Allogeneic Stem Cell Transplantation for Remission Induction in High-Risk Acute Myeloid Leukemia Patients within the Randomized Multi- Center Trial AML2003. (2008) (7)
A Strong Immune Effect by Allogeneic Stem Cell Transplantation May Improve Survival in AML Patients with a High Ratio of the FLT3-ITD Mutation to the Wt-FLT3 Allele: Results from an Analysis of 257 Patients Treated in the SAL AML-2003 Trial (2011) (7)
Recombinant IFN-α in Lymphomas (1990) (6)
Analysis of chimerism during the early period after allogeneic peripheral stem cell transplantation. (2001) (6)
Demonstration of the Fc-receptor of blood cells by soluble peroxidase-anti-peroxidase (PAP) complexes (1978) (6)
Current treatment modalities in advanced colorectal carcinoma. (1996) (6)
Recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to chemotherapy in aggressive non-Hodgkin's lymphomas. (1994) (6)
Routine immunophenotyping of acute leukemias (2005) (6)
CHOP and COPBLAM chemotherapy for diffuse large cell non‐Hodgkin's lymphomas: A retrospective comparison (1988) (6)
Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome (2021) (6)
Comparison of currently available monoclonal antibodies with conventional markers for phenotyping of one hundred acute leukemias (1982) (6)
Use of G-CSF in Patients with Severe Aplastic Anemia Treated with ATG and Cyclosporine Increases Neutrophils and Decreases Infection Rates and Hospitalization Days but Does Not Improve Long-Term Outcome: Results of a Prospective, Randomized Clinical Trial of the EBMT. (2009) (6)
Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma. (2001) (6)
High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma. (2007) (6)
Prognostic factors for chemotherapy-related toxicity in primary central nervous system lymphoma (PCNSL) treated with high-dose methotrexate (HDMTX) with or without ifosfamide: Results from a German phase III trial (G-PCNSL-SG-1). (2011) (6)
Lack of therapeutic effects of platelet activating factor antagonists in WEHI-3B leukemia, human xenotransplanted colorectal and lung cancer and Lewis-lung tumor in vivo. (1992) (6)
Auer-bodies in acute lymphocytic leukemia (ALL) [letter] (1980) (6)
Phase II study of liposomal daunorubicin and ifosfamide (IDx) as first line chemotherapy in soft tissue sarcoma (2004) (5)
[Recent aspects on the use of specific antisera in diagnosis and therapy of acute lymphatic leukaemia in infants (author's transl)]. (1979) (5)
A novel sporadic Burkitt lymphoma cell line (BLUE-1) with a unique t(6;20)(q15;q11.2) rearrangement. (2006) (5)
Antiviral cellular immunity in colorectal cancer patients. (2009) (5)
Evidence for monoclonal proliferation in prolymphocytic leukemia of T-cell orgin. A cytogenetic and Quantitative immunoautoradiographic analysis. (1977) (5)
NK-Cell Recovery and Immune Reconstitution after Haploidentical Hematopoietic Cell Transplantation Using Either CD34 Selected Grafts and Adoptive NK-Cell Transfer or CD3/CD19 Depleted Grafts: Comparison of Two Strategies for NK Cell Based Immunotherapy. (2007) (5)
A Multicenter Prospective Randomized Trial with Assessment of Quality of Life in Patients with Metastatic Colorectal Carcinoma Comparing Interferon α-2b and Folinic Acid as Modulators of 5-Fluorouracil (1994) (5)
Long term presence of a single predominant tyrosinase‐specific T‐cell clone associated with disease control in a patient with metastatic melanoma (2010) (5)
Isolated B-cell lymphoproliferative disorder at the dura mater with B-cell chronic lymphocytic leukemia immunophenotype. (2007) (5)
Detection of differential mitotic cell age in bone marrow CD34(+) cells from patients with myelodysplastic syndrome and acute leukemia by analysis of an epigenetic molecular clock DNA signature. (2010) (5)
[Leukemic cell phenotypes and the lymphoid differentiation pathway (author's transl)]. (1981) (5)
Surface expression of gpA33 is dependent on culture density and cell-cycle phase and is regulated by intracellular traffic rather than gene transcription. (2008) (5)
Evidence for monoclonal proliferation in prolymphocytic leukemia of T- cell origin (1977) (5)
GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells. (1992) (5)
Comparison of enzyme-cytochemical findings and immunological marker investigations in acute lymphatic leukemia (ALL) (1978) (4)
Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet! (2016) (4)
Chemotherapy of brain metastases. (1999) (4)
Expression of Normal and Leukemia-associated Antigens on Blood Cell Malignancies (1978) (4)
Heterogeneity of HRX-FEL Fusion Transcripts in Adult and Pediatric t(4;11) ALL (1996) (4)
Extensive leukemic kidney infiltration with membranoproliferative glomerulonephritis in a patient with B-cell chronic lymphocytic leukemia (2007) (4)
Heterologous group specific antiserum against Iak determinants. (1977) (4)
Characterization of antigens on acute lymphoblastic leukemias. (1979) (4)
Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNSL-SG1 randomized phase IV trial. (2010) (4)
[Rare variants of cutaneous T-cell lymphomas]. (1996) (4)
A phase II study of cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin (Myocet), and prednisone plus rituxmab (R-COMP) in elderly patients with diffuse large B-cell lymphoma (DLBCL). (2006) (4)
Interleukin-4 inhibits growth of a human lung-tumor cell-line in-vitro and has therapeutic activity against xenografts of this cell-line in-vivo. (1993) (4)
CS‐1, a novel c‐kithi+ acute myeloid leukemia cell line with dendritic cell differentiation capacity and absent immunogenicity (2003) (4)
[Diagnosis of acute leukemia with morphologic, immunologic and cytogenetic procedures]. (1993) (4)
Remission Induction Using Alemtuzumab can Permit Chemotherapy-refractory Chronic Lymphocytic Leukemia (CLL) Patients to Undergo Allogeneic Stem Cell Transplantation (2004) (4)
Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer. (2011) (4)
Patients Receiving IL-2 Activated Donor NK Cells Show Lower Incidence of Severe GvHD after Haploidentical SCT. (2007) (4)
Fresh peripheral blood mononuclear cell preparations are a better starting material than bone marrow after cryopreservation for immunomagnetic harvesting of CD34(+) hematopoietic cells. (1996) (4)
Long-term results of a phase-II-pilot trial on preoperative high-dose chemotherapy with stem cell rescue in patients with cancer of the upper gastrointestinal tract. (2001) (4)
Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer. (1997) (4)
MicroRNA Profiling Reveals Aberrant MicroRNA Expression in Adult ETP-ALL and Functional Studies Demonstrate a Role of Mir-222 in Acute Leukemia, (2011) (4)
PCR-Based Rapid Detection of the Philadelphia-Chromosome in Chronic Myelogenous and Acute Lymphoblastic Leukemia (1991) (4)
Liposomal anthracyclines and ifosfamide in the first line treatment of advanced soft tissue sarcomas: A two cohort phase II study. (2006) (4)
Generation of progenitor-cell precursors in long-term bone-marrow cultures after marrow purging with ether lipids. (1995) (4)
Quality of life (QL) is a prognostic factor (PF) for survival in patients with advanced colorectal cancer (CRC) (1997) (4)
Haemophagocytosis in bone marrow rhabdomyosarcoma (1999) (4)
Impressive response to temsirolimus in a patient with chemotherapy refractory diffuse large B-cell non-Hodgkin’s lymphoma (2010) (4)
Cost-Benefit Assessment of Antifungal Prophylaxis with Liposomal Amphotericin B in Neutropenic Patients (2007) (4)
Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: A randomized phase II trial (2005) (4)
Impact of response to chemotherapy and treating institution on survival in primary CNS lymphoma (PCNSL): Long-term results of the multicenter BMPD study. (2004) (4)
Possibilities and limitations of immunological marker analyses for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. (1990) (4)
Monoclonal antibodies in clinical hematology and oncology. (2007) (4)
IL-4 and TNF-α induce changes in integrin expression and adhesive properties and decrease the lung-colonizing potential of HT-29 colon carcinoma cells (1996) (4)
Ecto-5'-nucleotidase as a leukemia marker. (1984) (4)
Primary CNS lymphoma: chemotherapy followed by radiotherapy or chemotherapy alone? A randomized multicentric study. (1999) (4)
Melting Point Assay for the JAK2 V617F Mutation, Comparison with Amplification Refractory Mutation System (ARMS) in Diagnostic Samples, and Implications for Daily Routine (2010) (4)
Long-term survival in patients with primary CNS lymphoma: Results from the G-PCNSL-SG1 trial. (2015) (4)
International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) Study on Low-Grade Primary Central Nervous System Lymphoma in Immunocompetent Patients. (2005) (4)
[Letter to the editor]: whole-genome amplification of sodium bisulfite-converted DNA can substantially impact quantitative methylation analysis using pyrosequencing. (2011) (3)
Successful treatment of partial graft failure after matched unrelated donor stem cell transplantation by a combination of ancestim (stem cell factor) and granulocyte colony stimulating factor in a patient with heavily pre-treated chronic lymphocytic leukemia (2008) (3)
Recombinant human granulocyte-colony-stimulating factor (rhg-csf) does not stimulate in-vivo tumor-growth of the human colon-cancer cell-line htb 38 which is responsive in-vitro. (1993) (3)
Clinical and Immunological Activity of WT1 Peptide Vaccination in Patients with Acute Myeloid Leukemia and Myelodysplasia: Results of a Phase II Trial. (2006) (3)
In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors (2012) (3)
Is intestinal diffuse large b cell lymphoma a relatively benign disease? (2007) (3)
Prolymphocytic leukemia (1978) (3)
Hemosiderin deposits in chronic graft‐vs.‐host disease related myopathy (2005) (3)
The Role of Maintenance Chemotherapy, Immunotherapy, Induction Dose Reduction in Elderly Patients and Double Induction in the Treatment of Adult Acute Myeloid Leukemia. Four Randomized Studies of the AML Cooperative Group1 (1989) (3)
BCR rearrangement without juxtaposition of ABL in pre-T acute lymphoblastic leukaemia. (1996) (3)
Spezifisches Anti-T-Lymphocyten-Globulin (sATG) für die Diagnostik lymphoproliferativer Erkrankungen (1976) (3)
Protein synthesis in the blood lymphocytes of chronic lymphocytic leukemia and its relationship to prognosis (1982) (3)
Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma. (1996) (3)
G-PCNSL-SG-1 randomized phase III trial of high-dose methotrexate with or without whole brain radiotherapy for primary central nervous system lymphoma: Long-term follow-up. (2014) (3)
Bone Marrow Transplantation in Children with Aplastic Anemia and Acute Lymphatic Leukemia (1975) (3)
Bone marrow transplantation into recipients sensitized against donor-type T cells. (1980) (3)
Immunofluorescence with monoclonal antibodies on poly-L-lysine coated slides: an alternative to conventional methods (1983) (3)
Effect of vaccination of leukemia patients with a MHC class I peptide of Wilms tumor gene 1 (WT1) peptide with unspecific T helper stimulation on WT1-specific IgM responses and on IgG responses (2008) (3)
Biological and clinical significance of immunological cell markers in leukemia. (1984) (3)
Long distance polymerase chain reaction of ascites lymphoma cells aids diagnosis establishment of abdominal Burkitt's lymphoma and Burkitt-like lymphoma (2005) (3)
[Comparison of CHOP and COP-BLAM chemotherapy in highly malignant non-Hodgkin's lymphoma]. (2008) (3)
Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients. (2005) (3)
Primary CNS lymphoma and HLA class I and II alleles in a German cohort of immunocompetent patients (2008) (3)
Long-term remissions in relapsed/refractory primary central nervous system lymphoma (PCNSL) after topotecan chemotherapy (2005) (3)
Response of symptomatic brain metastases of small cell lung cancer (SCLC) to topotecan also after preceeding whole-brain radiation (WBI) (1999) (3)
A Novel Method to Quantify and Characterize Leukemia-Reactive Natural Killer Cells in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation following Conventional or Reduced-Dose Conditioning (2007) (3)
Inhibition of mast cell tryptase activity. A new therapeutic target against malignancy induced angiogenesis (2008) (3)
Risk groups in adult acute lymphoblastic leukemia. (1987) (3)
Chronic Graft versus Host Disease but not the Intensity of Conditioning has Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Hematological Diseases (2012) (3)
Systemic and intrathecal chemotherapy followed by high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT) for CNS relapse of aggressive lymphomas: A potentially curative approach? (2011) (3)
[Recruiting patients and results of a preliminary study on the therapy of acute lymphatic leukemia and acute undifferentiated leukemia in adults]. (1983) (2)
Augmentation of the Susceptibility of Human Leukemia to Lymphokine-Activated Killer (LAK) Cells by Exposure of the Leukemic Target Cells to Cytotoxic Drugs in Vitro and in Vivo. (1991) (2)
Frequency and Relevance of CD10+CD19+ Hematogones after Allogeneic Stem Cell Transplantation. (2008) (2)
Early T-Cell Precursor-ALL in Adult T-ALL. (2009) (2)
A Randomized Phase III Trial of Low Dose Liposomal Amphotericin B (L-AmB) as Prophylaxis of Invasive Fungal Infections (IFI) in Neutropenic Patients (pts). (2005) (2)
Phase II trial of vaccination with WT1 peptide, GM-CSF, and KLH in patients with acute myeloid leukemia and myelodysplasia: Final immunological, molecular, and clinical results (2007) (2)
1248 Use of methylene blue and bicarbonate in ifosfamide-related CNS toxicity. Case report (1995) (2)
Peroxidase expression in acute unclassified leukemias: ultrastructural studies in combination with immunophenotyping. (1994) (2)
Phase II study of liposomal daunorubicin and ifosfamide (IDx) as first line chemotherapy in soft tissue sarcoma. (2004) (2)
Diffuse Leukoencephalopathy and Brain Edema: Unusual Presentations of CNS Relapse of Acute Myeloid Leukemia (2010) (2)
Co-Expression of BAALC with ERG, TCF4, and CD133 Indicates a Shared Pathway in Acute Myeloid and Lymphoblastic Leukemia. (2005) (2)
Preclinical studies of T-cell-mediated immune responses against autologous tumor cells in patients with acute leukemia. (1993) (2)
The MYOCAN Study. A Phase II Study of Cyclophosphamide, Oncovin, Myocet™, and Prednisone Plus Rituximab (R-COMP) in the Treatment of Elderly Patients with Diffuse Large B-Cell Non-Hodgkin Lymphoma (DLBCL). (2004) (2)
Cytomorphological results and dysplastic features as prognostic factors in 41 cases with acute myeloid leukemia (AML) and translocation (1994) (2)
Activation of autologous lymphocytes of patients with chronic myelogenous leukemia in the chronic phase with cytokines and CD3 monoclonal antibody results in bcr/abl- blood leukocyte cultures as determined by reverse transcriptase-polymerase chain reaction. (1998) (2)
Penetration of Yttrium-90-Labeled Ibritumomab Tiuxetan (Zevalin™) into Primary CNS Lymphoma. (2006) (2)
Studies on chimaeric tolerance induced with anti-t-cell globulin. Abstr. (1974) (2)
Detection of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia by Analysis of Gene Rearrangements and Correlation with Early Relapses. (1991) (2)
Specific translocation t(4;11) in an infant with acute lymphoblastic leukaemia of null cell type (1983) (2)
Macrophage inflammatory protein (mip)-1-alpha stem-cell inhibitor (sci) does not affect clonal growth of human solid tumor-cell lines in-vitro. (1994) (2)
Therapeutic spectrum in the treatment of myelodysplastic syndromes (2004) (2)
Evaluation of 5′-nucleotidase as biochemical marker in leukemias and lymphomas (1983) (2)
Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine. (2010) (2)
Successful treatment of extracranially metastasized pineal gland germinoma with high-dose methotrexate. (2002) (2)
German-austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapy (1988) (2)
[Use of specific anti-T-lymphocyte globulin (sATG) for the diagnosis of lymphoproliferative diseases (author's transl)]. (1976) (2)
Quantitation of μ mRNA byin situ hybridization reveals a correlation between B-maturation associated antigens and IgM gene activation in acute lymphatic leukemias (1988) (2)
[Acute lymphatic leukemia in the adult. Diagnosis, risk groups and therapy]. (2002) (2)
Crossreaction of monoclonal Anti-T-cell antibodies: Implications for classifying B-cell leukemias (1983) (2)
Successful Treatment of High-Risk and Refractory Acute Myeloid Leukemia with haploidentical Stem Cell Transplantation Plus NK cell therapy (2010) (2)
Quantitation of antibody uptake on a group erythrocytes using immunoautoradiography and monoclonal IgM anti-A (1985) (2)
Four generation reproductive toxicity study with 2,3,7,8-tetrachlorodibenzo-P-dioxin (TCDD) in rats (2009) (2)
Reply to ‘NK cell subsets and CD107a mobilization assay’ by Zimmer et al (2005) (2)
[Diagnosis and prognosis of gonadal damage after chemotherapy and irradiation]. (1992) (2)
High BAALC Expression as an Independent Adverse Risk Factor in 309 Patients with Acute Myeloid Leukemia (AML) and Normal Cytogenetics: Results of the SHG’96 Study. (2004) (2)
Rapid detection of chimeric bcr/abl mRNAs in acute lymphoblastic and chronic myeloid leukemia by the polymerase chain reaction (1990) (1)
Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts Short title: GENETIC ANOMALIES IN MSCs OF MDS/AML PATIENTS (2011) (1)
Whole-brain radiotherapy in primary CNS lymphoma – Authors' reply (2011) (1)
Hyperdiploidy of 54 chromosomes with double Ph1 chromosome in lymphoid chronic myelocytic leukemic blast crisis. (1985) (1)
Addition of Histamine to IL-2 Treatment Augments T1 Cell-Funktion in Melanoma Patients In Vivo: Results from a Randomized Clinical Trial of IL-2 with or without Histamine (MP 104) (2004) (1)
Changes in 'A' antigenic sites in haematological disorders. An immunoautoradiographic study. (1985) (1)
B-cell lymphoma lacking Fc-and C3d-receptors (1978) (1)
Monoclonal antibodies against differentiation antigens of lymphopoiesis (1983) (1)
Phase-I tolerability study of 5-methyltetrahydrofolate in combination with a 4-hour infusion of 5-Fluorouracil in cancer-patients. (1995) (1)
[Immunophenotyping of acute lymphatic leukemia: diagnostic aspects and clinical relevance]. (1994) (1)
Lymphokine-activated killer (LAK) cells against human leukemia: augmentation of LAK-cell cytotoxicity by combinations of lymphokines or cytokines. (1990) (1)
Aplastic anemia: evidence of immuno-pathomechanisms and successful treatment with absorbed ATG. (1979) (1)
Expression of DNMT Isoforms Is Differentially Associated with Aberrant Promotor Methylation in MDS Hematopoietic Progenitor Cells during Lineage Specific Differentiation. (2006) (1)
Mast cell leukaemia (2005) (1)
High-dose methotrexate and ifosfamide for CNS relapse of aggressive lymphoma (2007) (1)
Rescue with recombinant Carboxypeptidase G2 (CPG2) in high-dose methotrexate (HD-MTX) induced renal failure: Results in 42 patients from a German emergency protocol. (2004) (1)
Addition of histamine to IL-2 treatment augments T1 cell-function in melanoma patients in vivo: results from a randomized clinical trial of IL-2 with or without histamine (MP 104) (2004) (1)
Cyclophosphamide, liposomal doxorubicin and dexamethasone (CLAD) is safe and efficacious in multiple myeloma (1999) (1)
Immunological diagnosis of leukemias and lymphomas : international symposium of the Institut für Hämatologie, GSF, October 28-30, 1976, Neuherberg/Munich (1977) (1)
Randomized trial of high-dose chemotherapy with autologous haematopoietic stem cell support vs. standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: Overall survival after 6 years of follow up. (2006) (1)
A prospective Multicenter study of the BMPD regimen with or without radiotherapy for primary CNS lymphoma. (2003) (1)
Phase II study of CLAD (cyclophosphamide, liposomal doxorubicin and dexamethasone) in patients with advanced multiple myeloma and historical comparison to CAD (cyclophosphamide, doxorubicin and dexamethasone) (2007) (1)
Monoclonal antibodies detecting plasminogen activators on the membrane of leukemic lymphoid cells of T-cell origin. (1987) (1)
Chronic graft-versus-host disease (GVHD) [proceedings]. (1978) (1)
5. Report on Workshop: Primary CNS Lymphoma (2001) (1)
CD44 variant isoforms in adult acute lymphoblastic leukemia : evidence for different splicing patterns according to the phenotype (1996) (1)
Treatment of Leukemic Meningeosis by CD 14 Depleted Adoptive Intrathecal Cell Therapy. (2008) (1)
Safety and Tolerance Data from the Belgian Multicentre Study of Anisoylated Plasminogen Streptokinase Acti vator Complex versus Heparin in Acute Myocardial (1987) (1)
CXCL12 and CXCL13 Levels in Cerebrospinal Fluid (CSF) of Patients with CNS Lymphoma. (2007) (1)
Quantifying Cell Adhesion of the Colon Cancer Cell Line HT 29 to Extracellular Matrix Proteins: Comparative Evaluation of an Isotopic, a Fluorometric, and a Colorimetric Method (1994) (1)
OMICS AND PROGNSTIC MARKERS (2013) (1)
Elderly patients with primary CNS lymphoma: Results from the G-PCNSL-SG-1 trial. (2012) (1)
Prognostic Impact of the Expression of the TLX1 (HOX11) and TLX3 (HOX11L2) Oncogenes in Adult ALL: Experience of the German Multicenter Acute Lymphoblastic Leukemia (GMALL) Therapy Study Group. (2004) (1)
Clinical bone marrow transplantation (BMT) in children with acute lymphoblastic leukemia (ALL). Presentation of cases (Munchen group) [proceedings]. (1978) (1)
Identification of ERG Specific Target Genes by Genome-Wide Screening in T-Lymphoblastic Leukemia (2008) (1)
A phase II trial of trimetrexate (TMTX), 5-fluorouracil (5-FU) and folinic acid (FA) in untreated patients with advanced colorectal carcinoma (1997) (1)
Low Expression of IL-15 in Adult B-Lineage Acute Lymphoblastic Leukemia Is Associated with Central Nervous System Involvement at Initial Presentation. (2007) (1)
Vaccination with the WT-1 126-134 Peptide in Patients with Acute Myeloid Leukemia after Allogenic Stem Cell Transplantation. (2006) (1)
Gene Expression Profiling Identifies IGFBP7 as a BAALC Co-Expressed Gene with a Functional Role in Acute Leukemia. (2009) (1)
IL-2 treatment decreases frequencies of IL-10-producing regulatory T cells type 1 (Tr1) (2006) (1)
Systemic Relapses In Primary CNS Lymphoma (PCNSL) - Unexpected Clonal Diversity (2010) (1)
Induction of lymphokine-activated killer cells against human leukemia cells in vitro (1989) (1)
General Condition and Early Complications Have in Addition to Disease- Specific Factors a Significant Impact on Outcome - Prognostic Factors Revisited in 1657 Adult ALL Patients (15–55 years). (2008) (1)
[2 unusual cutaneous T-cell lymphomas with extracutaneous involvement]. (1996) (1)
WT1-Specific T Cell Responses Are Frequent after Allogeneic Stem Cell Transplantation for Acute and Chronic Myeloid Leukemia. (2005) (1)
Phase I/II trial of gemcitabine plus treosulfan (GeT) in stage IV uveal melanoma and carcinomas. (2004) (1)
(GMALL) aberrations: results of the German Multicenter Trials for Adult ALL subgroup of adult ALL associated with a high frequency of MLL CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk (2013) (1)
[Effective treatment of anaemia with darbepoetin alfa in a patient with hereditary hemochromatosis]. (2004) (1)
Error management of emergency transfusions: a surveillance system to detect safety risks in day to day practice. (2006) (1)
Comparison of high-dose methotrexate (HDMTX) toxicity in elderly and younger patients (pts) with primary central nervous system lymphoma (PCNSL). (2004) (1)
Detection of Highly Clonal CD34 + , Mononuclear Bone Marrow and Peripheral Blood Cells From Patients with Myelodysplastic Syndrome and Age Related Increase of Clonal Hematopoiesis In Healthy Subjects Using a Novel Transcriptional Pyrosequencing Based Clonality Assay (2010) (1)
Impact of meningeal dissemination (MD) on outcome in primary CNS lymphoma in the G-PCNSL-SG1 trial. (2011) (1)
Antileukemic Activity of the HSP70 Inhibitor Pifithrin-μ (2010) (1)
Yttrium-90-labeled ibritumomab tiuxetan for primary CNS lymphoma. (2016) (1)
NK cell subsets and CD107a mobilization assay. Authors' reply (2005) (1)
[Electronmicroscopic and immunohistochemical studies on human lymphocytes]. (1976) (1)
Role of Mitoxantrone, High-Dose Cytosine Arabinoside, and Recombinant Human GM-CSF in Aggressive Non-Hodgkin’s Lymphoma (1992) (1)
Susceptibility of human leukemia cells to allogeneic and autologous lymphokine-activated killer cells and its augmentation by exposure of leukemia target cells to cytotoxic drugs in vitro and in vivo. (1993) (1)
Prospective evaluation of meningeal involvement in primary CNS lymphoma (PCNSL) (2008) (1)
CMV-Seropositive Patients Allografted with a CMV-Seronegative Donor Show Delayed or Missing CMV-Specific T-Cell Immune Response and Are at Higher Risk for CMV-Viremia and CMV-Disease. (2005) (1)
lnterferon-alpha2b for Early Phase Chronic Lymphocytic Leukemia with High Risk for Progression – First Results of a Randomized Multicenter AlO-Study (1992) (1)
[Interferon alfa-2B in chronic lymphatic leukemia of the B-cell type]. (1990) (1)
Molecular Analysis of the t(2;8)/MYC-IGK Translocation in High-Grade Lymphoma/Leukemia by Long-Distance Inverse PCR (2011) (1)
Recombinant human (rh) stem cell factor (SCF) does not stimulate clonal growth of human melanoma cell lines in vitro (1993) (1)
Detection of subclinical systemic disease in primary central nervous system lymphoma (PCNSL) by polymerase chain reaction (PCR) of the rearranged immunoglobulin heavy chain (IgH) genes. (2006) (1)
Interleukin-1 receptor antagonist inhibits growth modulation of human tumor-cell lines by interleukin-1 in-vitro. (1994) (1)
CD10 − Pre-B Acute Lymphoblastic Leukemia (ALL): A Distinct High-Risk Subgroup of Adult ALL. (2005) (1)
PHASE I TRIAL OF ADJUVANT VACCINATION WITH TYROSINASE PEPTIDES AND GM-CSF IN MELANOMA (1999) (1)
COMMONLY INACTIVATED BY DNA MUTATIONS AND DELETIONS IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (EMZL) (2008) (1)
The significance of ecto-5'-nucleotidase in lymphoid blast crisis of chronic myeloid leukemia. (1982) (1)
A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. (2006) (1)
HOX11L2 Genotyping Identifies Subset of Adult Thymic T-ALL with Inferior Outcome. (2005) (1)
Outcome of Adult ALL Patients with Fusion Transcript E2A-PBX1: Results from the GMALL Therapy Trials 5/93 and 6/99. (2006) (1)
Lymphoma Cells Are Highly Sensitive to Cytotoxic T-Cell-Killing Despite Presence of Multiple Resistance Mechanisms (2004) (1)
Mucosal Foxp3 + Regulatory T Cells Show Significant Numerical Differences in Patients with Intestinal Graft-Versus-Host Disease Compared to Infectious Diseases of the Gut. (2005) (1)
Long‐term follow‐up of peripheral blood stem cell transplantation from mismatched related and unrelated donors (2007) (1)
[Experience with voriconazole in invasive aspergillosis]. (2003) (1)
Treatment of Myeloid and Lymphoid Malignancies with Highly Purified Alloreactive CD56+CD3− NK-Cells and Haploidentical Stem Cell Transplantation: Promising Results of a Phase I Study. (2005) (1)
Clinical effects of Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1-expressing solid tumors as compared to patients with AML/MDS. (2011) (1)
WT1) peptide vaccination in patients with AML and MDS A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (2009) (1)
CNS-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT) for CNS relapse of aggressive lymphomas: Final analysis of a phase II study. (2012) (1)
AT-59HIGH-DOSE MTX-BASED CHEMOTHERAPY FOR PRIMARY CNS LYMPHOMA: WITH OR WITHOUT WHOLE BRAIN RADIOTHERAPY? FINAL ANALYSIS OF G-PCNSL-SG-1 (2014) (1)
Treatment of Minimal Residual Disease in Adult ALL: The German National Study (1986) (1)
Transcriptional Down-Regulation of the Wnt Antagonist SFRP1 Is Associated to Promoter Hypermethylation as Detected by Pyrosequencing in Hematopoietic Cells of Patients with Different Risk-Types of MDS, ALL and AML. (2009) (1)
[Incidence and significance of therapy-associated late toxicity in Hodgkin's disease]. (2008) (0)
Intestinal N on-Hodgkin's L ymphoma: A M ulticenter Prospective C linical S tudy F rom t he G erman S tudy G roup o n Intestinal N on-Hodgkin's L ymphoma (2003) (0)
Selective Uptake and Intracellular Distribution of Covalently Multimerized Human Stem Cell Factor (SCF)-Fusion Proteins into Human c-kit+ Acute Myeloid Leukemia (AML) Cells. (2007) (0)
Detection of Differential Mitotic Cell Ages in Bone Marrow CD34+ Cells Selected from Patients with Myelodysplastic Syndrome and Acute Leukemia by Pyrosequencing Analysis of An Epigenetic Molecular Clock DNA Signature (2008) (0)
Neoplastic meningeosis as connection with CNS involvement by solid tumors. Consequences for diagnosis and treatment (2008) (0)
Analysis of Factors Influencing Natural Killer (NK) Cell Activity during the Early Phase after Allogeneic Stem Cell Transplantation (SCT). (2005) (0)
The Susceptibility of Human Leukemia Cells to Allogeneic and Autologous Lymphokine-Activated Killer Cells and Augmentation of the Susceptibility by Exposure of Target Cells to Cytotoxic Drugs In Vitro and In Vivo (1992) (0)
Efficacy and Safety of Simultaneous Immunomagnetic CD 34 1 Cell Selection and Breast Cancer Cell Purging in Peripheral Blood Progenitor Cell Samples Used for Hematopoietic Rescue after High-Dose Therapy 1 (2000) (0)
High Anti-Tumor Activity of Natural Killer Cells after Non-Myeloablative Conditioning and Allogeneic Stem Cell Transplantation. (2006) (0)
[Multicenter prospective risk-adapted study on the therapy of non-Hodgkin's lymphomas of high malignancy. Use of COP-BLAM/IMVP-16 and randomized adjuvant radiotherapy--study concept and preliminary results]. (1988) (0)
Identification of MDS-Specific and Methylation Associated Downregulation of Survivine and WT1 in Highly Purified Hematopoietic Progenitor Cells during In Vitro Lineage Specific Differentiation. (2005) (0)
The Identification of ERG Related Pathways Pinpoints to Mechanisms Implicated in the Inferior Outcome of Acute T-Lymphoblastic Leukemia (T-ALL) with High ERG Expression. (2006) (0)
Adjuavnt tyrosinase peptide vaccination in patients with resected stage III/IV melanoma. (2006) (0)
Chemotherapy for Primary Central Nervous System Lymphoma (2012) (0)
9204 Toxicity of high-dose methotrexate (HDMTX) based chemotherapy in primary CNS lymphoma (PCNSL): preliminary experience from a randomized phase III study (G-PCNSL-SG1, NCT00153530) (2009) (0)
Physical activity for cancer patients (2008) (0)
Human Cytomegalovirus: Degranulation Is a Prominent Feature of Functionally Impaired pp65- and IE-1-Specific T-Cells in Patients after Allogeneic Stem Cell Transplantation (2008) (0)
[Standardized 125I-autoradiography for absolute measurements]. (1976) (0)
Analysis of Chromosomal Aberrations and DNA Mutations in Bone Marrow Mesenchymal Stroma Cells from Patients with Myelodysplastic Syndrome Amd Acute Myeloid Leukemia (2008) (0)
Bovine rotavirus. Kinetics of haemagglutinin formation and production of haemagglutinating preparations for use in the haemagglutination inhibition test with field serum samples of pigs and cattle. (1980) (0)
Abstracts of papers and posters advanced activities in pharmaceutical care 24th European Symposium on Clinical Pharmacy (1995) (0)
Molecular Characterization of Acute Undifferentiated and Biphenotypic Leukemia (2010) (0)
Improved outcome in CNS aspergillosis, using voriconazole [5] (2006) (0)
Survival and treatment patterns in patients (pts) with locally advanced or metastatic NSCLC treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIS): Analysis of US insurance claims databases (2019) (0)
Title Pages / Table of Contents (2010) (0)
A Novel Intravenous Catheter with Self-Operating Pretransfusion Blood Sampling for Enhanced Transfusion Safety: Retrospective Risk Analysis and Prospective Phase II Trial in Emergency Care (2008) (0)
8th Annual Meeting of the German Working Group for Gene Therapy (DAG-GT e.V.) (2014) (0)
Molecular characteristics of FLT3 mut ETP-ALL versus FLT3 wt ETP-ALL patients. (2013) (0)
[ALL-Associated antigen: occurrence on normal blood cells, cell-lines and leukaemic cells (author's transl)]. (1978) (0)
HIGH FREQUENCIES OF TUMOR-REACTIVE CD8+ T CELLS IN MELANOMA AND COLON CANCER PATIENTS (1999) (0)
Phase II pilot trial of preoperative high-dose chemotherapy in patients with malignant tumors of the upper gastrointestinal tract. (1996) (0)
Conditioning with Treosulfan and Cyclophosphamide without Application of Antibodies in MHC Mismatch Transplantations in Mice. (2006) (0)
[Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study]. (1989) (0)
Acknowledgement to Reviewers (2007) (0)
A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high-grade non-Hodgkin's lymphoma and cardiac risk factors. (2004) (0)
Genome Wide Screening Reveals Distinct Signaling Pathways of the ETS Transcription Factor ERG In Primary Acute Leukemia Blasts (2010) (0)
Primary Central Nervous System Lymphoma (PCNSL): Intent-to-Treat Analysis of Monocenter Long-Term Experience. (2007) (0)
Even With Minute Cerebrospinal Fluid Cell Specimens (2017) (0)
GM-CSF Stimulates IL-8 Expression in Human Bone Marrow Stromal Cells Via Activation of NADPH Oxidases. (2007) (0)
Overall Outcome of Relapsed Acute Lymphoblastic Leukemia Can Be Improved by Stem Cell Transplantation and Early Treatment in Stage of Molecular Relapse (2011) (0)
T-cell phenotypes in mixed leukocyte reactions and after bone marrow transplantation: are Ia-antigen on T-cells a marker for GvH reactions? (1983) (0)
Expression of Adhesion Molecules on Blood Derived CD34 Positive Cells Immediately After Thawing and After Ex Vivo Incubation with Cytokines (1997) (0)
Low-Dose Cytosine Arabinoside Regimen Adapted to the FAB Classifications of Myelodysplastic Syndromes: Is it Superior to Uniform Treatment for all Types of MDS? (1992) (0)
Chemotherapy for Adult Acute Myeloid Leukemia: Study Results from the Acute Myeloid Leukemia Cooperative Group and Overview (1993) (0)
Detection of circulating tumor cells by RT-PCR as a prognostic factor for distant metastases and survival uveal melanoma (2006) (0)
Frequency and prognostic value of dysmyelopoiesis in 114 patients with de novo acute myeloid leukemia (AML) in an ongoing study (1994) (0)
Degranulation of T-Cells Specific for the CMV-Proteins pp65 and IE-1 in Allogeneic Stem Cell Recipients. (2006) (0)
A Shift in the Intestinal Microflora towards Pro-Inflammatory Bacteria and Signaling Via Toll-Like-Receptor 2 Triggers Early Onset of Graft-Versus-Host Disease. (2007) (0)
Ifosfamide and trofosfamide for intraocular lymphoma (2005) (0)
Toll-Like Receptors 2 and 4 Are Involved in the Induction of Graft-Versus-Host-Disease in Mice. (2006) (0)
The significance of ecto-59-nucleotidase in lymphoid blast crisis of chronic myeloid leukemia [letter] (1982) (0)
Skewed X-Inactivation Patterns in Aging Healthy and Myelodysplastic Hematopoiesis Determined By a Novel Transcriptional Clonality Assay (0)
Book reviews (2005) (0)
[Immunological examination of lymphocytes in patients with sarcoidosis and bronchial asthma (author's transl)]. (1979) (0)
Response of Early Stage B-CLL to Interferon-α:2 Years Experience of a Pilot Study (1990) (0)
Low Dose Liposomal Amphotericin B (L-AmB) as Prophylaxis of Invasive Fungal Infections (IFI) in Neutropenic Patients (pts): Is It Cost Effective?. (2006) (0)
voriconazole treatment Improved outcome in central nervous system aspergillosis, using (2013) (0)
Consequent Iron Chelation Therapy in Patients with Low Risk Myelodysplastic Syndrome Leads to up-Regulation of .CXCL12, JAK2 and HSF2: Possible Link Between Iron Chelation and Improvement of Erythropoiesis. (2009) (0)
Differential Expression of ERG Isoforms in Acute Myeloid and T-Lymphoblastic Leukemia Is Regulated by DNA-Methylation. (2007) (0)
Epigenetic Dysregulation of GATA1 but Not Downstream Notch Effectors is Involved in MDS Dyserythropoiesis. (2008) (0)
rituximab therapy Fatal hepatitis B virus reactivation by an escape mutant following (2011) (0)
Contents Vol. 58, 2000 (2000) (0)
Leukemia. Recent developments in diagnosis and therapy. (1984) (0)
Quantitative $sup 125$I-autoradiography of individual cells (1975) (0)
Factors influencing blood group antigen estimation by immunoautoradiography. (1986) (0)
Result of the chromosomal anomaly (2010) (0)
A Novel BACH2-BCL2L1 Fusion Gene in the Burkitt’s Lymphoma Derived Cell Line BLUE-1 (2008) (0)
Central nervous system involvement in non-Hodgkin’s lymphoma: A single-center analysis of prognostic factors for survival (2005) (0)
Adjuvant Tyrosinase Peptide Vaccination in Combination with GM-CSF and KLH for Induction of Specific T Cell Responses in Melanoma (2004) (0)
Interferon Alfa in the treatment of B-cell chronic lymphocytic leukemia (1994) (0)
[Leukemia cell analysis in the diagnosis of ALL/AUL: clinical value of currently available methods]. (1986) (0)
Peptide vaccination induces specific effector and memory T cells but fails to enhance preexisting T cell immunity (2004) (0)
Does psychotherapy affect the survival of cancer patients? More questions than answers. (2007) (0)
Leukaemic transformation of F1-hybrid cells after inoculation of parental leukaemic cells (1975) (0)
CCR6 Expression Levels in Colorectal Cancer are Strongly Associated With Liver Metastasis (2005) (0)
Appearance of B- or T-lymphocyte markers after diffusion chamber culture of acute lymphoblastic leukemia cels (1981) (0)
Survivin Isoforms and HSP90 Are Downregulated in Erythropoiesis during Lineage Specific Differentiation of MDS Hematopoietic Progenitor Cells. (2006) (0)
[Therapy of malignant lymphoma]. (1990) (0)
Wilms Tumor 1 Gene Mutations in Adult Acute T-Lymphoblastic Leukemia (2008) (0)
Mutations in the regulatory domains of bcr/abl-positive leukemias detected by solid-phase automated DNA sequencing. (1993) (0)
Mutations in Specific NOTCH1 Domains Convey a Distinct Phenotype in Adult Acute T-Lymphoblastic Leukemia. (2007) (0)
Promotor Demethylation as a Mechanism of HOX11 Activation in Adult T-ALL?. (2006) (0)
[Immunohistochemical findings in malignant lymphatic system diseases]. (1977) (0)
Lymphocyte surface markers profile in acute lymphoblastic leukaemia. (1987) (0)
[Diagnostik significance of cell membrane markers in childhood ALL (author's transl)]. (1978) (0)
Dose intensity phase III trial with ifosfamide, carboplatin, etoposide, and vincristine combined with filgastrim (CEV-Ifo + G) in patients with small-cell lung cancer (SCLC) (1998) (0)
Induction of apoptosis and growth inhibition in myeloid malignancies by arsenic trioxide (As203) (2000) (0)
FLT3-ITD Mutations in AML: Structural and Numerical Variation of Mutations and Identification of Subgroup with Poor Prognosis (2011) (0)
and chronic GvHD regulatory T cells are numerically deficient in acute + Mucosal FOXP3 (2011) (0)
Vaccination of Patients with Recurrent AML with WT1-Peptide Induces Clinical and Molecular Remissions as Well as Specific Memory and Effector T Cells in Peripheral Blood and Bone Marrow (2004) (0)
Detailed Genome-Wide DNA-Mapping of CD34+ Cells Purified from Patients with MDS Using High-Resolution SNP Arrays Identifies Significant Regions of Genomic Alterations. (2006) (0)
[Intensive combined therapy for high-risk ALL patients]. (1988) (0)
PCR of immunoglobulin heavy-chain (IgH) complementary determining region III (CDRIII) for diagnosis of meningeal dissemination (MD) in primary CNS lymphoma (PCNSL): A prospective evaluation (2007) (0)
Gene Expression Profiling by Microarrays: Foreword (2006) (0)
Genetic variants of folate and methionine metabolism and primary central nervous system lymphoma incidence in a German cohort of 185 patients (2009) (0)
Immune self-tuning in renal cell carcinoma patients. (2009) (0)
Primary Mediastinal Large B-Cell Lymphoma: Long Term Results with an Alternating Chemotherapy Regimen Based on High-Dose Methotrexate. (2004) (0)
Correlation between the expression of myelomonocytic surface antigens and ultrastructural demonstration of early myeloperoxidase expression in null-AL(L) cells. (1990) (0)
Interleukin-2-Induced Lymphokine-Activated Killer (LAK) Cells Against Human Leukemia: Improvement of Cytotoxicity by Combinations of Lymphokines or Cytokines (1990) (0)
[T-cell leukemias of adulthood]. (1976) (0)
WT1-Peptide Vaccination in Patients With Acute Myeloid Leukemia Shows High Immunogenicity Associated With Clinical Activity (2005) (0)
Differential expression of chemokine receptors in primary central nervous system and extracerebral lymphomas (2005) (0)
Ifosfamide or trofosfamide in patients with intraocular lymphoma: Final report (2008) (0)
7142 Immune tuning in renal cell carcinoma patients (2009) (0)
Quantitative Analysis of Wilms’ Tumor Gene 1(WT1) Expression in Acute Lymphoblastic Leukemia (ALL) of Adults Reveals Lower WT1 Levels Than in Acute Myeloid Leukemias (AML) and Varying Expression Levels between Individual Patients among Different ALL Subgroups. (2005) (0)
Patterns of Cell Surface Differentiation of cALL Positive Leukemic Blast Cells in Diffusion Chamber Culture (1981) (0)
Influence of Recombinant Human lnterleukin-10 (IL-10) on the Clonal Growth of Human Malignant Lymphoid Cell Lines and Cell Lines from Human Solid Tumors in vitro (1994) (0)
Session III: Allogeneic blood stem cell transplantation in hematologic malignancies and solid tumors (1999) (0)
Salvage Therapy of Adult ALL (1996) (0)
Analysis of Immunological and Clinical Response Kinetics to WT1 Peptide Vaccine in Patients with AML and MDS: Need for Supplementation of IWG Response Criteria?. (2007) (0)
Biologic Determinants for AML Therapy (1998) (0)
ORIGINAL ARTICLE Antileukemic activity of the HSP70 inhibitor pifithrin-l in acute leukemia (2011) (0)
The MLL Recombinome of Adult ALL - Results from the GMALL Study Group. (2007) (0)
Vaccination with WT1 induces high frequency memory and effector T cells in peripheral blood and bone marrow associated with complete remission of recurrent AML (2004) (0)
A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high grade non-Hodgkins lymphoma (2007) (0)
Early Thymic Progenitor Leukemia (ETP-ALL) in Adults: A Distinct Molecular Entity, (2011) (0)
[Treatment of adult acute lymphoblastic leukemia]. (1999) (0)
[Late cardiac toxicity in Hodgkin's disease. A study with pulsed Doppler echocardiography]. (2008) (0)
P069 Genome-wide DNA-mapping of CD34+ cells from MDS patients with 500K SNP arrays identifies significant regions of genomic alterations (2007) (0)
Interferon-α in the Treatment of B-Cell Chronic Lymphocytic Leukemia (1994) (0)
Acid phosphatase in acute lymphatic leukemia (ALL). (1977) (0)
leukemia in adults Intensified therapy in acute lymphoblastic and acute undifferentiated (2011) (0)
Human Bone Marrow as a Source of Multifunctional CMV-Specific CD4+ T Cells for Adoptive Cell Therapy. (2007) (0)
PET/MRI fusion in primary central nervous system lymphoma: Initial results of a prospective study (2006) (0)
Simultaneous Double-Purging of Breast Cancer Cells from Leukapheresis Products by Immunomagnetic CD34+ Cell Enrichment and Tumor Cell Depletion (2000) (0)
F-18-labeled fluorodeoxyglucose positron emission tomography for evaluation of disease extent, response to treatment and follow-up in primary CNS lymphoma (2007) (0)
Immune escape mechanisms in patients with AML receiving WT1 peptide vaccination (2008) (0)
Management of primary intraocular lymphoma (PIOL): Results from the prospective German PIOL registry (PIOL-R). (2012) (0)
Prolymphocytic leukemia with suppressor T-cell phenotype: report of two cases. (1989) (0)
Long term efficacy of WT1 peptide vaccine in patients with WT1 overexpressing hematopoeitic and solid malignancies (2013) (0)
[Systemic therapy of cerebral metastases in breast carcinoma]. (1991) (0)
Malignant melanoma--clinical development of peptide-based melanoma vaccines. (2006) (0)
ERG Overexpression Induces Cell Adhesion Mediated Drug Resistance in Acute Leukemia (2011) (0)
Characteristics and survival in patients with metastasic uveal melanoma: Analysis of a referral center cohort. (2011) (0)
targeted therapy for Stauffer's Syndrome in a patient with renal cell carcinoma : P208 (2010) (0)
GM-CSF Can Modulate the Migratory Phenotype of Vaccine-Induced T Cells by Enhancing CXCR3 Expression (2005) (0)
Yttrium-90-labeled ibritumomab tiuxetan (Zevalin(R)) for primary CNS lymphoma (2006) (0)
Detection of residual leukemic cells in adult acute lymphoblastic leukemia by analysis of gene rearrangements and correlation with early relapses. (1993) (0)
Real-Time Quantitative Y Chromosome Specific PCR vs. XY-FISH vs. Fluorescent STR-PCR for Chimerism Analysis after Allogeneic Sex-Mismatched PBSCT. (2004) (0)
Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial (2011) (0)
Identification of Highly Clonal Cells in CD34+ and Unselected Bone Marrow Samples From Patients with Myelodysplastic Syndrome Using a Sensitive Quantitative PCR Approach. (2009) (0)
[Bone marrow transplantation in a case of subtotal marrow strophy (panmyelopathy)]. (1976) (0)
Brain metastases in non-small cell lung cancer patients at the time of first diagnosis: Therapy and outcome. (2010) (0)
Recombinant Human Interleukin 4 Has Antiproliferative Activity on Human Tumor Cell Lines Derived from Epithelial and Nonepithelial Histologies 1 (2006) (0)
Prediction of Response to Treatment with Lenalidomide in Patients with Non-Del 5q Myelodysplastic Syndrome by Gene Expression Profiling Remains Difficult. (2009) (0)
Efficacy of transarterial chemoembolization (TACE) of liver metastases from uveal melanoma (2008) (0)
first presentation and in relapse Analyses of phenotype and genotype in acute lymphoblastic leukemias at (2011) (0)
Fusion Protein on Malignant and Normal Hematopoietic Cells Differential Effects of a Stem Cell Factor-Immunoglobulin (2013) (0)
Cell surface differentiation of acute lymphoblastic cALL-type leukemias in diffusion chambers (1979) (0)
Significant Down-Regulation of BAALC during Lineage Specific Hematopoietic Differentiation. (2004) (0)
ASSERTING THE MONOCLONALITY OF LYMPHOPROLIFERATIVE DISORDERS (1985) (0)
313 Incidence and severity of anaemia in patients with primary lymphoma of the central nervous system treated with high-dose methotrexate (2003) (0)
Mesenchimal Stroma Cells From Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia Show Distinct Cytogenetic and DNA-Mutation Data as Compared with Bone Marrow Leukemic Blasts. (2009) (0)
Randomized , Double-Blind , Placebo-Controlled , Phase I 11 Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as Adjunct to Induction Treatment of High-Grade Malignant Non-Hodgkin ' s Lymphomas (2003) (0)
Cytogenetic Risk Groups and Minimal Residual Disease Are Strong Prognostic Factors for Post-Transplant Outcome in Patients with Acute Myeloid Leukaemia and Myelodysplastic Syndrome (2011) (0)
Poley S, et al: Serum β2-microglobulin for staging and monitoring of multiple myelomas and other non-Hodgkin lymphomas. Onkologie 1994;17:428-432. (1994) (0)
Auer bodies in acute lymphocytic leukaemia and B-cell lymphoma: Evidence for a common progenitor of myeloid and lymphoid cells? (1981) (0)
Altered Growth Characteristics of Cord Blood Cells after in vivo Exposure to Maternal Acute Myeloid Leukemia and Chemotherapy (2005) (0)
5078 Treatment of leptomeningeal involvement of breast cancer with high-dose methotrexate and ifosfamide (2009) (0)
(A) Overview depicting the common exons 2 – 11 and the three transcript variants (TV) of exon 1 of (2011) (0)
Cytogenetic and Molecular Genetic Aberrations in Bone Marrow Mesenchymal Stroma Cells from Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. (2007) (0)
Prognostic significance of adult acute lymphoblastic leukemia phenotypes defined by monoclonal antibodies (1986) (0)
Ifosfamide for intraocular lymphoma. (2004) (0)
Low-Dose Aclacinomycin A in Myelodysplastic Syndromes and Subsequent Acute Myelogenous Leukemia: A Phase II Study (1990) (0)
Organ Siderosis In a Murine Graft-Versus-Host-Model After Allogeneic Stem Cell Transplantations Unrelated to Red Cell Transfusion (2010) (0)
Treatment of relapsed acute lymphoblastic leukemia (ALL): Improved results in GMALL studies but optimisation is an ongoing challenge (2011) (0)
New developments in cancer therapy: cytokines as modulators of cytotoxic drugs (1993) (0)
Meningeal Dissemination (MD) in Primary CNS Lymphoma (PCNSL): Multimodal Diagnosis, Presentation and Outcome in a Large Monocenter Patient Cohort (2008) (0)
8700 Subclinical systemic disease and relapse pattern in primary central nervous system lymphoma (PCNSL) (2009) (0)
Kongressberichte – Congress Reports (1994) (0)
Non-Functional (haploinsufficient), but Not Dominant Negative Clonal IKZF1 Deletions Confer an Adverse Prognosis in Adult BCR-ABL-Negative Acute Lymphoblastic Leukemia (2015) (0)
Antibacterial prophylaxis with levofloxacin in patients after allogeneic stem cell transplantation and neutrophil reconstitution: results from a double-blinded, placebo-controlled phase III trial and overview of recent clinical practice (2010) (0)
Risk groups in a multicenter pilot study for treatment of acute lymphoblastic and acute undifferentiated leukemia in adults. (1985) (0)
[Quantitative immunoautoradiography for the diagnosis of leukemias]. (1980) (0)
Induction of lymphokine-activated killer (LAK) cells against human leukemia cells. (1989) (0)
Treatment of minimal residual disease in adult acute lymphoblastic leukemia: The German national study (1986) (0)
Subject Index Vol. 58, 2000 (2000) (0)
Rescue with recombinant Carboxypeptidase G2 (CPG2) in high-dose methotrexate (HD-MTX) induced renal failure: Results in 42 patients from a German emergency protocol (2004) (0)
Alemtuzumab but Not ATG Decreases Natural Killer (NK) Cell Activity towards Tumor Targets in the Early Phase after Allogeneic Stem Cell Transplantation. (2006) (0)
[T-cell-antigen positive, E-rosette negative acute lymphoblastic leukaemia (author's transl)]. (1978) (0)
Quantification and Characterization of Peripheral Blood Natural Killer (NK) Cells Mediating Rituximab and Alemtuzumab Dependent Cytotoxicity. (2005) (0)
[Membrane differentiation of acute lymphoblastic leukemia from cALL-type cells in diffusion chambers]. (1983) (0)
MicroRNAs Are Differentially Expressed in Primary Central Nervous (CNS) and Nodal Diffuse Large B-Cell Lymphomas. (2009) (0)
Abstract No. 184: Transarterial Chemoembolization (TACE) of Liver Metastases from Uveal Melanoma: Evaluation of Efficacy and LDH as a Prognostic Factor (2009) (0)
Toxicity and Risk Factors Contributing to Delayed Methotrexate (MTX) Elimination in Adult/Elderly Patients (pts) Treated with High-Dose Methotrexate Therapy (HDMTX), a 2-Year, Single Center Survey. (2006) (0)
[Deposits of immunoglobulins in the cells of chronic lymphocytic leukemia (author's transl)]. (1975) (0)
CXCL13 and CXCL12 in central nervous system (CNS) lymphoma patients. (2016) (0)
[Thrombocytopenic purpura with platelet antibodies against acetylsalicylic acid]. (1973) (0)
Clinical prognostic factors for distant metastases and survival in patients with primary uveal melanoma: A 10-year follow-up of a single center cohort study (2007) (0)
Bone Marrow Transplantation in Aplastic Anaemia (1974) (0)
Overexpression of BAALC Indicates Drug Resistance and Inferior Survival in Adult B-Precursor Acute Lymphoblastic Leukemia. (2009) (0)
[Bone marrow transplantation for aplastic anaemia (author's transl)]. (1981) (0)
High Expression of IL-15 Correlates with Disease Recurrence of Adult B-Lineage Acute Lymphoblastic Leukemia (2008) (0)
High serum levels of sCD23 and sCD25 in early stage B-CLL correlate with clinical characteristics predictive for progressive disease (1994) (0)
Combination of mitoxantrone and etoposide in the Treatment of Advanced MyelodysplasticSyndrome/Secondary Acute Myeloid Leukemia - a Multicenter Phase II Study (2002) (0)
Differences in Foxp3+ regulatory T cells in patients with intestinal graft-versus-host (GvH) disease, inflammatory bowel disease and infectious diseases (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Eckhard Thiel?

Eckhard Thiel is affiliated with the following schools:

Eckhard Thiel's Academic­Influence.com Rankings

Eckhard Thiel's Degrees

Why Is Eckhard Thiel Influential?

Eckhard Thiel's Published Works

Published Works

What Schools Are Affiliated With Eckhard Thiel?

Eckhard Thiel's AcademicInfluence.com Rankings